InNexus Biotechnology (InNexus Biotechnology) ROCE % : 0.00% (As of Mar. 2011)

View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InNexus Biotechnology's annualized ROCE % for the quarter that ended in Mar. 2011 was 0.00%.

InNexus Biotechnology ROCE % Historical Data

The historical data trend for InNexus Biotechnology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology ROCE % Chart

InNexus Biotechnology Annual Data

Trend

Jun01

Jun02

Jun03

Jun04

Jun05

Jun06

Jun07

Jun08

Jun09

Jun10

ROCE %

Get a 7-Day Free Trial

-325.68

-150.81

-104.42

-230.13

InNexus Biotechnology Quarterly Data
	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

InNexus Biotechnology ROCE % Calculation

InNexus Biotechnology's annualized ROCE % for the fiscal year that ended in Jun. 2010 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2010 )		(A: Jun. 2009 )		(A: Jun. 2010 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2010 )		(A: Jun. 2009 )		(A: Jun. 2010 )
	=	-3.788	/	( ( (4.158 - 3.578)	+	(3.312 - 8.255) )	/ 2 )
	=	-3.788	/	( (0.58	+	-4.943)	/ 2 )
	=	-3.788	/	-2.1815
	=	173.64 %

InNexus Biotechnology's ROCE % of for the quarter that ended in Mar. 2011 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2011 )		(Q: Dec. 2010 )		(Q: Mar. 2011 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2011 )		(Q: Dec. 2010 )		(Q: Mar. 2011 )
	=	-1.264	/	( ( (3.313 - 8.864)	+	(3.237 - 9.541) )	/ 2 )
	=	-1.264	/	( ( -5.551	+	-6.304 )	/ 2 )
	=	-1.264	/	-5.9275
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2011) EBIT data.

InNexus Biotechnology (GREY:IXSBF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InNexus Biotechnology ROCE % Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

InNexus Biotechnology (InNexus Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7

Website

http://www.ixsbio.com

InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology (InNexus Biotechnology) Headlines

No Headlines